Development of multiexon skipping antisense oligonucleotide therapy for duchenne muscular dystrophy

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Aoki, Yoshitsugu ^a   Yokota, Toshifumi ^b   Wood, Matthew J A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN;

ARTICLE; CARDIOMYOPATHY; CAUSE OF DEATH; CHEMICAL STRUCTURE; CONGESTIVE CARDIOMYOPATHY; DUCHENNE MUSCULAR DYSTROPHY; DYSPNEA; EXON; EXON SKIPPING; FATIGUE; GENE MUTATION; HUMAN; MYALGIA; MYOBLAST; MYOGLOBINURIA; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; OLIGONUCLEOTIDE THERAPY; ONSET AGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; TOXICITY TESTING; WALKING DIFFICULTY; WEAKNESS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG SCREENING; GENETICS; MUSCULAR DYSTROPHY, DUCHENNE; REVIEW;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DYSTROPHIN; EXONS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE;

EID: 84883155329     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/402369     Document Type: Article

References (74)

1. Arahata K., Ishiura S., Ishiguro T., Tsukahara T., Suhara Y., Eguchi C., Ishihara T., Nonaka I., Ozawa E., Sugita H., Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 1988 333 6176 861 863 2-s2.0-0023877613
2. Wood M. J. A., Toward an oligonucleotide therapy for duchenne muscular dystrophy: a complex development challenge. Science Translational Medicine 2010 2 25 25 ps15 2-s2.0-77953017904 10.1126/scitranslmed.3000512
3. Aartsma-Rus A., Fokkema I., Verschuuren J., Ginjaar I., van Deutekom J., van Ommen G.-J., Den Dunnen J. T., Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation 2009 30 3 293 299 2-s2.0-61649097962 10.1002/humu.20918
4. Hoffman E. P., Bronson A., Levin A. A., Takeda S., Yokota T., Baudy A. R., Connor E. M., Restoring dystrophin expression in duchenne muscular dystrophy muscle: progress in exon skipping and stop codon read through. The American Journal of Pathology 2011 179 1 12 22 2-s2.0-80052513011 10.1016/j.ajpath.2011. 03.050
5. McClorey G., Moulton H. M., Iversen P. L., Fletcher S., Wilton S. D., Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Therapy 2006 13 19 1373 1381 2-s2.0-33745479703 10.1038/sj.gt.3302800
6. Saito T., Nakamura A., Aoki Y., Yokota T., Okada T., Osawa M., Takeda S., Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS ONE 2010 5 8 2-s2.0-77957913755 10.1371/journal. pone.0012239 e12239
7. Dunckley M. G., Manoharan M., Villiet P., Eperon I. C., Dickson G., Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Human Molecular Genetics 1998 7 7 1083 1090 2-s2.0-0031800293 10.1093/hmg/7.7.1083
8. Aartsma-Rus A., De Winter C. L., Janson A. A. M., Kaman W. E., van Ommen G.-J. B., Den Dunnen J. T., van Deutekom J. C. T., Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 2005 15 4 284 297 2-s2.0-30844436415 10.1089/oli.2005.15.284
9. Arechavala-Gomeza V., Graham I. R., Popplewell L. J., Adams A. M., Aartsma-Rus A., Kinali M., Morgan J. E., van Deutekom J. C., Wilton S. D., Dickson G., Muntoni F., Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Human Gene Therapy 2007 18 9 798 810 2-s2.0-34848904544 10.1089/hum.2006.061
10. Wilton S. D., Lloyd F., Carville K., Fletcher S., Honeyman K., Agrawal S., Kole R., Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscular Disorders 1999 9 5 330 338 2-s2.0-0033044501 10.1016/S0960-8966(99)00010-3
11. van Deutekom J. C. T., Bremmer-Bout M., Janson A. A. M., Ginjaar I. B., Baas F., Den Dunnen J. T., van Ommen G.-J. B., Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Human Molecular Genetics 2001 10 15 1547 1554 2-s2.0-0035878539
12. Matsuo M., Masumura T., Nishio H., Nakajima T., Kitoh Y., Takumi T., Koga J., Nakamura H., Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy Kobe. The Journal of Clinical Investigation 1991 87 6 2127 2131 2-s2.0-0026046262
13. Aoki Y., Nakamura A., Yokota T., Saito T., Okazawa H., Nagata T., Takeda S., In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Molecular Therapy 2010 18 11 1995 2005 2-s2.0-78049472917 10.1038/mt.2010.186
14. Alter J., Lou F., Rabinowitz A., Yin H., Rosenfeld J., Wilton S. D., Partridge T. A., Qi L. L., Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Medicine 2006 12 2 175 177 2-s2.0-32244443828 10.1038/nm1345
15. Lu Q. L., Rabinowitz A., Chen Y. C., Systemic delivery of antisense oligoribonucleotide restorers dystrophin expression in body-wide skeletal muscles. Proceedings of the National Academy of Sciences of the United States of America 2005 102 1 198 203 2-s2.0-11844256373 10.1073/pnas.0406700102
16. Aoki Y., Yokota T., Nagata T., Nakamura A., Tanihata J., Saito T., Duguez S. M. R., Nagaraju K., Hoffman E. P., Partridge T., Takeda S., Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proceedings of the National Academy of Sciences of the United States of America 2012 109 34 13763 13768
17. Yokota T., Lu Q.-L., Partridge T., Kobayashi M., Nakamura A., Takeda S., Hoffman E., Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Annals of Neurology 2009 65 6 667 676 2-s2.0-63449141811 10.1002/ana.21627
18. Yokota T., Nakamura A., Nagata T., Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acids Research 2012 22 5 306 315 10.1089/nat.2012.0368
19. Yin H., Moulton H. M., Betts C., Merritt T., Seow Y., Ashraf S., Wang Q., Boutilier J., Wood M. J. A., Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Molecular Therapy 2010 18 10 1822 1829 2-s2.0-77957605909 10.1038/mt.2010.151
20. Wu B., Lu P., Benrashid E., Malik S., Ashar J., Doran T. J., Lu Q. L., Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Therapy 2010 17 1 132 140 2-s2.0-74349109205 10.1038/gt.2009.120
21. Mitrpant C., Fletcher S., Iversen P. L., Wilton S. D., By-passing the nonsense mutation in the 4CV mouse model of muscular dystrophy by induced exon skipping. Journal of Gene Medicine 2009 11 1 46 56 2-s2.0-59449107366 10.1002/jgm.1265
22. Fletcher S., Honeyman K., Fall A. M., Harding P. L., Johnsen R. D., Wilton S. D., Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligunucleotide. Journal of Gene Medicine 2006 8 2 207 216 2-s2.0-32844460899 10.1002/jgm.838
23. Goyenvalle A., Babbs A., Powell D., Kole R., Fletcher S., Wilton S. D., Davies K. E., Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Molecular Therapy 2010 18 1 198 205 2-s2.0-74149093605 10.1038/mt.2009.248
24. Cirak S., Arechavala-Gomeza V., Guglieri M., Feng L., Torelli S., Anthony K., Abbs S., Garralda M. E., Bourke J., Wells D. J., Dickson G., Wood M. J., Wilton S. D., Straub V., Kole R., Shrewsbury S. B., Sewry C., Morgan J. E., Bushby K., Muntoni F., Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. The Lancet 2011 378 9791 595 605 2-s2.0-80051690306 10.1016/S0140-6736(11)60756-3
25. Goemans N. M., Tulinius M., van Den Akker J. T., Burm B. E., Ekhart P. F., Heuvelmans N., Holling T., Janson A. A., Platenburg G. J., Sipkens J. A., Sitsen J. M. A., Aartsma-Rus A., van Ommen G.-J. B., Buyse G., Darin N., Verschuuren J. J., Campion G. V., Kimpe S. J. D., van Deutekom J. C., Systemic administration of PRO051 in Duchenne's muscular dystrophy. The New England Journal of Medicine 2011 364 16 1513 1522 2-s2.0-79955158683 10.1056/NEJMoa1011367
26. Bushby K., Finkel R., Birnkrant D. J., Case L. E., Clemens P. R., Cripe L., Kaul A., Kinnett K., McDonald C., Pandya S., Poysky J., Shapiro F., Tomezsko J., Constantin C., Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology 2010 9 1 77 93 2-s2.0-72149108443 10.1016/S1474-4422(09)70271-6
27. Hoffman E. P., Brown R. H. Jr., Kunkel L. M., Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987 51 6 919 928 2-s2.0-0023614188
28. Yoshida M., Hama H., Ishikawa-Sakurai M., Imamura M., Mizuno Y., Araishi K., Wakabayashi-Takai E., Noguchi S., Sasaoka T., Ozawa E., Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Human Molecular Genetics 2000 9 7 1033 1040 2-s2.0-17344382194
29. Ozawa E., Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era. Proceedings of the Japan Academy Series B 2010 86 8 798 821 2-s2.0-77958557373 10.2183/pjab.86.798
30. Heald A., Anderson L. V. B., Bushby K. M. D., Shaw P. J., Becker muscular dystrophy with onset after 60 years. Neurology 1994 44 12 2388 2390 2-s2.0-0028027687
31. Monaco A. P., Bertelson C. J., Liechti-Gallati S., Moser H., Kunkel L. M., An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988 2 1 90 95 2-s2.0-0023718118
32. Baumbach L. L., Chamberlain J. S., Ward P. A., Farwell N. J., Caskey C. T., Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology 1989 39 4 465 474 2-s2.0-0024580404
33. Gillard E. F., Chamberlain J. S., Murphy E. G., Duff C. L., Smith B., Burghes A. H. M., Thompson M. W., Sutherland J., Oss I., Bodrug S. E., Klamut H. J., Ray P. N., Worton R. G., Molecular and phenotypic analysis of patients with deletions within the deletion-rich region of the Duchenne muscular dystrophy (DMD) gene. American Journal of Human Genetics 1989 45 4 507 520 2-s2.0-0024430346
34. Koening M., Beggs A. H., Moyer M., Scherpf S., Heindrich K., Bettecken T., Meng G., Muller C. R., Lindlof M., Kaariainen H., De la Chapelle A., Kiuru A., Savontaus M.-L., Gilgenkrantz H., Recan D., Chelly J., Kaplan J.-C., Covone A. E., Archidiacono N., The molecular basis for Duchenne versus becker muscular dystrophy: correlation of severity with type of deletion. American Journal of Human Genetics 1989 45 4 498 506 2-s2.0-0024466501
35. Dias N., Stein C. A., Antisense oligonucleotides: basic concepts and mechanisms. Molecular Cancer Therapeutics 2002 1 5 347 355 2-s2.0-0000015743
36. Iversen P. L., Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Current Opinion in Molecular Therapeutics 2001 3 3 235 238 2-s2.0-0034939942
37. Heemskerk H., De Winter C., van Kuik P., Heuvelmans N., Sabatelli P., Rimessi P., Braghetta P., van Ommen G.-J. B., De Kimpe S., Ferlini A., Aartsma-Rus A., van Deutekom J. C., Preclinical PK and PD studies on 2 ′ -O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Molecular Therapy 2010 18 6 1210 1217 2-s2.0-77953134497 10.1038/mt.2010.72
38. Pramono Z. A. D., Takeshima Y., Alimsardjono H., Ishii A., Takeda S.-I., Matsuo M., Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochemical and Biophysical Research Communications 1996 226 2 445 449 2-s2.0-0030582315 10.1006/bbrc.1996.1375
39. Takeshima Y., Wada H., Yagi M., Ishikawa Y., Ishikawa Y., Minami R., Nakamura H., Matsuo M., Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain & Development 2001 23 8 788 790 2-s2.0-0035196165 10.1016/S0387-7604(01)00326-6
40. Takeshima Y., Yagi M., Wada H., Matsuo M., Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle. Brain & Development 2005 27 7 488 493 2-s2.0-25644449483 10.1016/j.braindev.2004.12.006
41. Yin H., Lu Q., Wood M., Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Molecular Therapy 2008 16 1 38 45 2-s2.0-37549022222 10.1038/sj.mt.6300329
42. Yin H., Betts C., Saleh A. F., Ivanova G. D., Lee H., Seow Y., Kim D., Gait M. J., Wood M. J. A., Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Molecular Therapy 2010 18 4 819 827 2-s2.0-77950518145 10.1038/mt.2009.310
43. Aartsma-Rus A., Kaman W. E., Bremmer-Bout M., Janson A. A. M., den Dunnen J. T., van Ommen G.-J. B., van Deutekom J. C. T., Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Therapy 2004 11 18 1391 1398 2-s2.0-4644227797 10.1038/sj.gt.3302313
44. Renneberg D., Bouliong E., Reber U., Schümperli D., Leumann C. J., Antisense properties of tricyclo-DNA. Nucleic Acids Research 2002 30 13 2751 2757 2-s2.0-0036640332
45. Morcos P. A., Li Y., Jiang S., Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. BioTechniques 2008 45 6 613 623 2-s2.0-58149339903 10.2144/000113005
46. Wu B., Li Y., Morcos P. A., Doran T. J., Lu P., Lu Q. L., Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Molecular Therapy 2009 17 5 864 871 2-s2.0-67349137953 10.1038/mt.2009.38
47. Morcos P. A., Li Y., Jiang S., Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. BioTechniques 2008 45 6 613 623 2-s2.0-58149339903 10.2144/000113005
48. Ivanova G. D., Fabani M. M., Arzumanov A. A., Abes R., Yin H., Lebleu B., Wood M., Gait M. J., PNA-peptide conjugates as intracellular gene control agents. Nucleic Acids Symposium Series 2008 52 31 32 10.1093/nass/nrn016 2-s2.0-65449167777
49. Betts C., Saleh A. F., Arzumanov A. A., Hammond S. M., Godfrey C., Coursindel T., Gait M. J., Wood M. J., Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Molecular Therapy. Nucleic Acids 2012 1 8 e38 10.1038/mtna.2012.30
50. van Deutekom J. C., Janson A. A., Ginjaar I. B., Frankhuizen W. S., Aartsma-Rus A., Bremmer-Bout M., Den Dunnen J. T., Koop K., van der Kooi A. J., Goemans N. M., De Kimpe S. J., Ekhart P. F., Venneker E. H., Platenburg G. J., Verschuuren J. J., van Ommen G.-J. B., Local dystrophin restoration with antisense oligonucleotide PRO051. The New England Journal of Medicine 2007 357 26 2677 2686 2-s2.0-37549034298 10.1056/NEJMoa073108
51. Kinali M., Arechavala-Gomeza V., Feng L., Cirak S., Hunt D., Adkin C., Guglieri M., Ashton E., Abbs S., Nihoyannopoulos P., Garralda M. E., Rutherford M., Mcculley C., Popplewell L., Graham I. R., Dickson G., Wood M. J., Wells D. J., Wilton S. D., Kole R., Straub V., Bushby K., Sewry C., Morgan J. E., Muntoni F., Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology 2009 8 10 918 928 2-s2.0-69949107887 10.1016/S1474-4422(09)70211-X
52. Goemans N., Klingels K., van den Hauwe M., van Orshoven A., Vanpraet S., Feys H., Buyse G., Test-retest reliability and developmental evolution of the 6-min walk test in Caucasian boys aged 5-12 years. Neuromuscular Disorders 2013 23 1 19 24
53. Arechavala-Gomeza V., Graham I. R., Popplewell L. J., Adams A. M., Aartsma-Rus A., Kinali M., Morgan J. E., van Deutekom J. C., Wilton S. D., Dickson G., Muntoni F., Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Human Gene Therapy 2007 18 9 798 810 2-s2.0-34848904544 10.1089/hum.2006.061
54. Aartsma-Rus A., Fokkema I., Verschuuren J., Ginjaar I., van Deutekom J., van Ommen G.-J., Den Dunnen J. T., Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Human Mutation 2009 30 3 293 299 2-s2.0-61649097962 10.1002/humu.20918
55. Yokota T., Takeda S., Lu Q.-L., Partridge T. A., Nakamura A., Hoffman E. P., A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Archives of Neurology 2009 66 1 32 38 2-s2.0-58449122870 10.1001/archneurol.2008.540
56. Ferreiro V., Giliberto F., Noelia Muñiz G. M., Francipane L., Marzese D. M., Mampel A., Roqué M., Frechtel G. D., Szijan I., Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle and Nerve 2009 39 2 239 243 2-s2.0-60549088537 10.1002/mus.21193
57. Tselikas L., Rodrigues E., Jammal M., Tiev K., Chayet C., Josselin-Mahr L., Gain M., Toledano C., Cabane J., Kettaneh A., Late onset Becker muscular dystrophy. A case report and literature review. La Revue de Médecine Interne 2011 32 3 181 186 2-s2.0-79951683118 10.1016/j.revmed.2010.10.353
58. Béroud C., Tuffery-Giraud S., Matsuo M., Hamroun D., Humbertclaude V., Monnier N., Moizard M.-P., Voelckel M.-A., Calemard L. M., Boisseau P., Blayau M., Philippe C., Cossée M., Pagès M., Rivier F., Danos O., Garcia L., Claustres M., Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Human Mutation 2007 28 2 196 202 2-s2.0-33846924058 10.1002/humu.20428
59. Aoki Y., Yokota T., Nagata T., Nakamura A., Tanihata J., Saito T., Duguez S. M. R., Nagaraju K., Hoffman E. P., Partridge T., Takeda S., Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proceedings of the National Academy of Sciences of the United States of America 2012 109 34 13763 13768 10.1073/pnas.1204638109
60. Koenig M., Kunkel L. M., Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. Journal of Biological Chemistry 1990 265 8 4560 4566 2-s2.0-0025217703
61. Yokota T., Duddy W., Partridge T., Optimizing exon skipping therapies for DMD. Acta Myologica 2007 26 3 179 184
62. Anthony K., Cirak S., Torelli S., Tasca G., Feng L., Arechavala-Gomeza V., Armaroli A., Guglieri M., Straathof C. S., Verschuuren J. J., Aartsma-Rus A., Helderman-van den Enden P., Bushby K., Straub V., Sewry C., Ferlini A., Ricci E., Morgan J. E., Muntoni F., Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011 134 12 3547 3559 2-s2.0-84857091039
63. Gentil C., Leturcq F., Ben Yaou R., Kaplan J. C., Laforet P., Pénisson-Besnier I., Espil-Taris C., Voit T., Garcia L., Piétri-Rouxel F., Variable phenotype of del45-55 Becker patients correlated with nNOS mislocalization and RYR1 hypernitrosylation. Human Molecular Genetics 2012 21 15 3449 3460 10.1093/hmg/dds176
64. Nakamura A., Yoshida K., Fukushima K., Ueda H., Urasawa N., Koyama J., Yazaki Y., Yazaki M., Sakai T., Haruta S., Takeda S., Ikeda S.-I., Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. Journal of Clinical Neuroscience 2008 15 7 757 763 2-s2.0-44249125023 10.1016/j.jocn.2006.12.012
65. Yokota T., Hoffman E., Takeda S., Antisense oligo-mediated multiple exon skipping in a dog model of duchenne muscular dystrophy. Methods in Molecular Biology 2011 709 299 312 2-s2.0-79960055339 10.1007/978-1-61737-982-6-20
66. van Vliet L., de Winter C. L., van Deutekom J. C. T., van Ommen G.-J. B., Aartsma-Rus A., Assessment of the feasibility of exon 45-55 multiexon skipping for duchenne muscular dystrophy. BMC Medical Genetics 2008 9, article 105 2-s2.0-58149350004 10.1186/1471-2350-9-105
67. Araki E., Nakamura K., Nakao K., Kameya S., Kobayashi O., Nonaka I., Kobayashi T., Katsuki M., Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in duchenne muscular dystrophy. Biochemical and Biophysical Research Communications 1997 238 2 492 497 2-s2.0-0031577559 10.1006/bbrc.1997.7328
68. Partridge T. A., The mdx mouse model as a surrogate for Duchenne muscular dystrophy. The FEBS Journal 2013 10.1111/febs.12267
69. Owczarzy R., Tataurov A. V., Wu Y., Manthey J. A., McQuisten K. A., Almabrazi H. G., Pedersen K. F., Lin Y., Garretson J., McEntaggart N. O., Sailor C. A., Dawson R. B., Peek A. S., IDT SciTools: a suite for analysis and design of nucleic acid oligomers. Nucleic Acids Research 2008 36 W163 W169 2-s2.0-48449105928 10.1093/nar/gkn198
70. Koo T., Wood M., Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Human Gene Therapy 2013 24 5 479 488 10.1089/hum.2012.234
71. Melacini P., Vianello A., Villanova C., Fanin M., Miorin M., Angelini C., Dalla Volta S., Cardiac and respiratory involvement in advanced stage duchenne muscular dystrophy. Neuromuscular Disorders 1996 6 5 367 376 2-s2.0-0030273734 10.1016/0960-8966(96)00357-4
72. Melacini P., Fanin m. F. M., Danieli G. A., Fasoli G., Villanova C., Angelini C., Vitiello L., Miorelli M., Buja G. F., Mostacciuolo M. L., Pegoraro E., Dalla Volta S., Cardiac involvement in Becker muscular dystrophy. Journal of the American College of Cardiology 1993 22 7 1927 1934 2-s2.0-0027377342
73. Bushby K., Muntoni F., Bourke J. P., 107th ENMC International Workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscular Disorders 2003 13 2 166 172 2-s2.0-0037304994 10.1016/S0960-8966(02)00213-4
74. Miyazaki D., Yoshida K., Fukushima K., Nakamura A., Suzuki K., Sato T., Takeda S., Ikeda S.-I., Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene. Journal of Human Genetics 2009 54 2 127 130 2-s2.0-60749109887 10.1038/jhg.2008.8